Literature DB >> 28648913

The effects of analgesics on central processing of tonic pain: A cross-over placebo controlled study.

Dina Lelic1, Tine M Hansen2, Esben B Mark3, Anne E Olesen4, Asbjørn M Drewes5.   

Abstract

INTRODUCTION: Opioids and antidepressants that inhibit serotonin and norepinephrine reuptake (SNRI) are recognized as analgesics to treat moderate to severe pain, but the central mechanisms underlying their analgesia remain unclear. This study investigated how brain activity at rest and exposed to tonic pain is modified by oxycodone (opioid) and venlafaxine (SNRI).
METHODS: Twenty healthy males were included in this randomized, cross-over, double-blinded study. 61-channel electroencephalogram (EEG) was recorded before and after five days of treatment with placebo, oxycodone (10 mg extended release b.i.d) or venlafaxine (37.5 mg extended release b.i.d) at rest and during tonic pain (hand immersed in 2 °C water for 80 s). Subjective pain and unpleasantness scores of tonic pain were recorded. Spectral analysis and sLORETA source localization were done in delta (1-4 Hz), theta (4-8 Hz), alpha (8-12 Hz), beta1 (12-18 Hz) and beta2 (18-32 Hz) frequency bands.
RESULTS: Oxycodone decreased pain and unpleasantness scores (P < 0.05), whereas venlafaxine decreased the pain scores (P < 0.05). None of the treatments changed the spectral indices or brain sources underlying resting EEG. Venlafaxine decreased spectral indices in alpha band of the EEG to tonic pain, whereas oxycodone decreased the spectral indices and brain source activity in delta and theta frequency bands (all P < 0.05). The brain source activity predominantly decreased in the insula and inferior frontal gyrus.
CONCLUSION: The decrease of activity within insula and inferior frontal gyrus is likely involved in pain inhibition due to oxycodone treatment, whereas the decrease in alpha activity is likely involved in pain inhibition due to venlafaxine treatment.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Brain source localization; EEG; LORETA; Opioid; SNRI

Mesh:

Substances:

Year:  2017        PMID: 28648913     DOI: 10.1016/j.neuropharm.2017.06.022

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  6 in total

Review 1.  Recent advances in objectifying pain using neuroimaging techniques.

Authors:  J Archibald; F M Warner; O Ortiz; M Todd; C R Jutzeler
Journal:  J Neurophysiol       Date:  2018-05-16       Impact factor: 2.714

2.  Differential effects of oxycodone and venlafaxine on resting state functional connectivity-A randomized placebo-controlled magnetic resonance imaging study.

Authors:  Tine M Hansen; Dina Lelic; Anne E Olesen; Asbjørn Mohr Drewes; Jens B Frøkjaer
Journal:  CNS Neurosci Ther       Date:  2018-02-21       Impact factor: 5.243

3.  The molecular neurobiology and neuropathology of opioid use disorder.

Authors:  Christopher A Blackwood; Jean Lud Cadet
Journal:  Curr Res Neurobiol       Date:  2021-10-14

4.  Variability and effect sizes of intracranial current source density estimations during pain: Systematic review, experimental findings, and future perspectives.

Authors:  Juan Manuel Völker; Federico Gabriel Arguissain; Ole Kaeseler Andersen; José Biurrun Manresa
Journal:  Hum Brain Mapp       Date:  2021-02-19       Impact factor: 5.038

5.  Neuronal Effects of Listening to Entrainment Music Versus Preferred Music in Patients With Chronic Cancer Pain as Measured via EEG and LORETA Imaging.

Authors:  Andrea McGraw Hunt; Jörg Fachner; Rachel Clark-Vetri; Robert B Raffa; Carrie Rupnow-Kidd; Clemens Maidhof; Cheryl Dileo
Journal:  Front Psychol       Date:  2021-02-25

6.  Improved cognitive function in patients with major depressive disorder after treatment with vortioxetine: A EEG study.

Authors:  Hong Kim; Seung Yeon Baik; Yong Wook Kim; Seung-Hwan Lee
Journal:  Neuropsychopharmacol Rep       Date:  2021-12-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.